Gilead has opened its new $11 million manufacturing facility control lab in Ireland.

The FDA has OK’d the Daewoong manufacturing plant that will make Evolus’ Botox rival but rejected Evolus' biologic over its manufacturing design.

The EMA pulled the license of Taiwan’s Savior Lifetec Corp. after a plant inspection in March turned up a variety of problems.

China’s new drug approval rules appear to have set off a biologics production race, leading CMOs in China to make large investments in plant projects.

President Trump's push to force price tags into drug advertising has pharma marketers worried and full of questions.

After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of $1.8 billion anemia drug Epogen,

Gilead will locate the European manufacturing site for its CAR-T therapy Yescarta at a Netherlands airport to ensure quick turnaround for its patients.

French CDMO Novasep says it needs a new fill-finish facility for low-volume biologics, so it will build one at its site in Seneffe, Belgium.

Canada-based Apotex has agreed to merge its Australian business with that of India’s Strides Shasun.